The Efficacy and Safety of Zhigancao Tang Granule for HFpEF of Qi-Yin Dificiency

Heart Failure With Preserved Ejection Fraction Clinical Trial

— HFpEF  

Official title:

A Randomized，Double-blinded, Placebo-controlled Trial Evaluating the Efficacy and Safety of Zhigancao Tang Granule for HFpEF of Qi-Yin Dificiency

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04317339
• Other study ID #: ZGCT
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: March 20, 2020
• Est. completion date: March 31, 2022

Study information

• Verified date: November 2019
• Source: Shanghai University of Traditional Chinese Medicine
• Contact: Bing Deng, M.D
• Phone: 8618917763110
• Email: dengbing82[@]sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was designed as a randomized, double blinded and placebo-controlled clinical trial. The aim of the study is to evaluate the efficacy and safety of Zhigancao Tang granule in patients with HFpEF of Qi-Yin dificiency.

Description:

Heart failure with preserved ejection fraction (HFPEF) is a clinical syndrome characterized by diastolic dysfunction.The incidence of HFpEF is increasing in recent years. Standard treatment of heart failure does not improve the prognosis of HFPEF patients. Zhigancao Tang was used to improve the symptoms of chronic heart failure in China.This randomized,double-blinded and placebo-controlled trial will objectively and standardly evaluate the effectiveness and safety of Zhigancao Tang granule.After 12 weeks of treatment, 122 HFpEF patients with deficiency of Qi and Yin were observed and evaluated in terms of heart function, clinical symptoms,exercise tolerance and quality of life.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 122
• Est. completion date: March 31, 2022
• Est. primary completion date: March 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Comply with the diagnostic criteria of Western medicine for HFpEF and the diagnostic criteria for TCM syndromes of Qi-Yin deficiency;

2. Cardiac function classification by NYHA: grade I to III;

3. Age between 30 and 80 years old;

4. Those who volunteer to participate in clinical trial observation, sign informed consent and indicate date;

5. During the observation period, those who do not take other drugs other than those specified and can insist on completing the treatment and observation.

Exclusion Criteria:

1. Valvular heart disease, restrictive cardiomyopathy, pericardial disease;

2. Decompensated heart failure is unstable after treatment;

3. Combined with atrial fibrillation;

4. Patients with severe lung, liver, endocrine system and kidney dysfunction;

5. Patients with cancer and other common malignant diseases reducing life expectancy;

6. Pregnant or lactating women;

7. Allergic constitution or allergic history to common drugs;

8. Patients with mental illness or poor compliance of traditional Chinese medicine treatment.

Related Conditions & MeSH terms

• Heart Failure
• Heart Failure With Preserved Ejection Fraction

Intervention

Drug:
• Zhigancao Tang granule
Zhigancao Tang: Dissolve Zhigancao Tang granule in 200ml hot water, twice a day,12 weeks, oral. Standard heart failure treatment,including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed.
• Zhigancao Tang placebo granule
Zhigancao Tang placebo: Dissolve Zhigancao Tang placebo granule in 200ml hot water, twice a day,12 weeks, oral. Standard heart failure treatment,including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed.

Locations

Country	Name	City	State
China	Longhua Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai University of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cardiac Functional Grading	Significant effect: cardiac function recovered to level 1 or increased by level 2; Effective: cardiac function increased by level 1 but failed to reach level 2; Ineffective: cardiac function did not change; Worsening: cardiac function decreased by level 1 or above.	12 weeks
Secondary	Ultrasonic cardiogram	Echocardiographic measurement of Left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDd), left ventricular end systolic diameter (LVESD), ratio of left ventricular early diastolic fast filling peak to late diastolic filling peak (E / a), ratio of early diastolic velocity of mitral valve to early diastolic annular velocity (E / E ').	12 weeks
Secondary	6-min walking test (6mwt)	6 minute walking test (6mwt) is a measure of the distance the patient can reach as far as possible by walking on a hard ground without obstacles within six minutes at the fastest possible speed. It provides a comprehensive assessment of exercise capacity.	12 weeks
Secondary	Minnesota Heart Failure Quality of Life Scale	Minnesota Heart Failure Quality of Life Scale was used to assess the impact of heart failure on life in the last four weeks. A total of 21 questions related to physical and emotional change. Higher scores mean a worse outcome.	12 weeks
Secondary	N-terminal pro-B-type natriuretic peptide(NT-proBNP)	NT-proBNP is a reliable and sensitive indicator of heart failure. Its elevation is positively correlated with severity of heart failure.	12 weeks
Secondary	TCM syndrome score	TCM syndrome score is used to assess changes in Qi-Yin Dificiency related symptoms during treatment. The higher the scores, the more heart failure symptoms. Higher scores mean a worse outcome.	12 weeks